Sign up to our newsletter Subscribe
We found for
Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies

Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies
